Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review

Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review

Infections due to carbapenem-resistant Enterobacterales (CRE) are increasingly prevalent in children and are associated with poor clinical outcomes, especially in critically ill patients. Novel beta lactam antibiotics, including ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, i...

Full description

Bibliographic Details
Main Authors:	Francesco Venuti, Lorenza Romani, Maia De Luca, Costanza Tripiciano, Paolo Palma, Maria Chiriaco, Andrea Finocchi, Laura Lancella
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Microorganisms
Subjects:	children pediatric multidrug resistant Gram-negative bacteria infections ceftolozane/tazobactam
Online Access:	https://www.mdpi.com/2076-2607/11/7/1798

Similar Items

Satisfactory In Vitro Activity of Ceftolozane<tt>–</tt>Tazobactam against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> But Not against <i>Klebsiella pneumoniae</i> Isolates
by: Alicja Sękowska, et al.
Published: (2023-03-01)

In vitro activity of ceftolozane/tazobactam against Gram-negative bacilli isolated from pediatric patients: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017–2021, China
by: Xinli Mu, et al.
Published: (2024-09-01)

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa
by: Adnan Alatoom, et al.
Published: (2017-09-01)

Evaluation of in-vitro susceptibility of ß-lactam-resistant Gram-negative bacilli to ceftazidime-avibactam and ceftolozane-tazobactam from clinical samples of a general hospital in southern Brazil
by: Thaisa Noceti Carvalho, et al.
Published: (2023-01-01)

Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study
by: Thamer A. Almangour, et al.
Published: (2022-03-01)

Antimicrobial susceptibility of gram-negative bacteria: Analysis from patients in a laboratory network in Brazil
by: Amanda Azevedo Bittencourt, et al.
Published: (2025-03-01)

Whole Genome Sequencing of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistant Pseudomonas aeruginosa Isolated from a Blood Stream Infection Reveals VEB and Chromosomal Metallo-Beta Lactamases as Genetic Determinants: A Case Report
by: Alamri AM, et al.
Published: (2020-11-01)

In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait
by: Wadha Alfouzan, et al.
Published: (2018-09-01)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020-02-01)

In vitro activity of ceftolozane/tazobactam against Gram‐negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries—SMART 2017–2019
by: Sibylle H. Lob, et al.
Published: (2022-06-01)

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
by: François Barbier, et al.
Published: (2023-07-01)

Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam
by: Jade L. L. Teng, et al.
Published: (2024-08-01)

Use of Ceftolozane/Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia
by: Ahmed Zikri, et al.
Published: (2019-05-01)

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa
by: Adrian J. Brink, et al.
Published: (2022-10-01)

Ceftolozane/tazobactam: Literature review of its activity on Taiwanese isolates before its launch in Taiwan (2012–2021)
by: Chien-Ming Chao, et al.
Published: (2024-07-01)

Antimicrobial activity of cefepime-tazobactam combination against extended spectrum beta-lactamase and/or AmpC beta-lactamase- producing gram-negative bacilli
by: Basma Ahmed Elawady, et al.
Published: (2024-04-01)

A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections
by: Yihong Sun, et al.
Published: (2022-10-01)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017-01-01)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
by: C. Weber, et al.
Published: (2022-10-01)

Activity of Ceftolozane-Tazobactam Against Gram-Negative Isolates from Australia and New Zealand as part of the PACTS Surveillance 2016-2018
by: Dee Shortridge, et al.
Published: (2022-12-01)

In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations
by: Anne Santerre Henriksen, et al.
Published: (2024-08-01)

Multicenter surveillance of antimicrobial susceptibilities and resistance mechanisms among Enterobacterales species and non-fermenting Gram-negative bacteria from different infection sources in Taiwan from 2016 to 2018
by: Shio-Shin Jean, et al.
Published: (2022-06-01)

Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy
by: Wasim S. El Nekidy, et al.
Published: (2024-07-01)

Clinical and microbiological features of ceftolozane/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy
by: Gianluca Morroni, et al.
Published: (2022-09-01)

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study
by: Camille Mané, et al.
Published: (2020-05-01)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
by: Abdullah Tarık Aslan, et al.
Published: (2022-02-01)

Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study
by: Claire Rempenault, et al.
Published: (2021-06-01)

Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
by: James A. Karlowsky, et al.
Published: (2021-03-01)

Baicalein Resensitizes Multidrug-Resistant Gram-Negative Pathogens to Doxycycline
by: Yuhang Wang, et al.
Published: (2023-06-01)

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study
by: Hakeam A. Hakeam, et al.
Published: (2022-10-01)

Antimicrobial activity of cephalosporin–beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Pseudomonas aeruginosa strains
by: Amani M. Alnimr, PhD, et al.
Published: (2020-06-01)

Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales
by: Agnès B. Jousset, et al.
Published: (2023-03-01)

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
by: Yuta Ibe, et al.
Published: (2023-08-01)

Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections
by: Eliana S. Armstrong, et al.
Published: (2016-11-01)

In vitro susceptibility of Burkholderia pseudomallei isolates from Thai patients to ceftolozane/tazobactam and ceftazidime/avibactam
by: Wantin Sribenjalux, et al.
Published: (2022-03-01)

Ceftolozane/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa
by: Meredith Tate Romano, et al.
Published: (2020-01-01)

In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals
by: Nezar M. Bahabri, et al.
Published: (2022-04-01)

Intravenous Colistin Use for Multidrug-Resistant Gram-Negative Infections in Pediatric Patients
by: Ayşe Karaaslan, et al.
Published: (2016-12-01)

Use of Newer and Repurposed Antibiotics against Gram-Negative Bacteria in Neonates
by: Angeliki Kontou, et al.
Published: (2023-06-01)

What to Do with the New Antibiotics?
by: Khalil Chaïbi, et al.
Published: (2023-03-01)